ctDNA evaluation may play a prognostic role in stage III colon cancer treated with celecoxib

Time to metastasis after prostatectomy should not be used as a prognostic factor for metachronous mHSPC

Combining chemotherapy with cemiplimab for advanced penile cancer may serve as a viable first-line treatment option

KIM-1 is a good prognostic and predictive biomarker in advanced renal cell carcinoma

Addition of trastuzumab to chemo does not provide significant survival benefit in HER-2 positive stomach cancer

UGN-102 shows better results after 12 months of treatment for low-grade intermediate-risk NMIBC

177Lu-PSMA-617 with concomitant ARPIs shows is more efficacious than SoC in mCRPC

CaboNivo shows sustained long-term benefits for survival and tumour progression as a 1L treatment of aRCC

HSD3B1 inheritance reduces OS in high-risk nmPC patients on ADT enzalutamide, abiraterone acetate plus prednisolone

Nivolumab plus ipilimumab shows superior efficacy in metastatic colorectal compared to nivolumab monotherapy

Everolimus plus lanreotide might be a new standard treatment in the first-line setting for grade 1/2 GEP-NETs

Gemcitabine/nab-paclitaxel compared with 5-fluorouracil/leucovorin/liposomal irinotecan shows similar results in older patients